REVIEW An antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. Ritonavir is a peptidomimetic inhibitor of both the HIV-1 and HIV-2 proteases. Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor which leads to production of non-infectious immature HIV particles.
Cooper C, la Porte C, Tossonian H, Sampalis J, Ackad N, Conway B (2012). A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study. HIV Clin Trials. 13(4):179-88. PMID 22849960.
Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM (2012). Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 60(2):158-64. PMID 22627182.